The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | B | Blood and blood forming organs | |
| 2 | B02 | Antihemorrhagics | |
| 3 | B02A | Antifibrinolytics | |
| 4 | B02AB | Proteinase inhibitors | |
| 5 | B02AB02 | Alfa1 antitrypsin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| PAREN - Parenteral | 0.6 g |
| Active Ingredient | Description | |
|---|---|---|
| Alfa1 antitrypsin |
Human alpha1-proteinase inhibitor is understood to be the primary anti-protease in the lower respiratory tract, where it inhibits neutrophil elastase (NE). Normal healthy individuals produce sufficient alpha1-proteinase inhibitor to control the NE produced by activated neutrophils and are thus able to prevent inappropriate proteolysis of lung tissue by NE. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| PROLASTIN-C Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RESPREEZA Powder and solvent for solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
